Artivion, Inc. (AORT) 10-Year Financial Performance & Capital Metrics

AORT • • Industrial / General

HealthcareMedical DevicesCardiovascular DevicesVascular & Aortic Devices

AboutArtivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.Show more

Revenue $389M +9.8%
EBITDA $63M +118.9%
Net Income -$13M +56.5%
EPS (Diluted) -0.32 +57.3%
Gross Margin 64.03% -1.1%
EBITDA Margin 16.23% +99.4%
Operating Margin 10.01% +516.8%
Net Margin -3.44% +60.3%
ROE -4.79% +55.8%
ROIC 5% +586.7%
Debt/Equity 1.31 +3.1%
Interest Coverage 1.13 +399.7%

Technical Analysis

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y10.39%

5Y7.06%

3Y9.14%

TTM9.81%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-974.15%

EPS CAGR

10Y-

5Y-

3Y-

TTM-991.44%

ROCE

10Y Avg2.83%

5Y Avg1.69%

3Y Avg2.33%

Latest5.34%

Peer Comparison

Vascular & Aortic Devices

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
PENPenumbra, Inc.	13.73B	350.49	973.58	12.86%	12.3%	12.07%	1.07%	0.19
NVNOenVVeno Medical Corporation	6.35M	0.31	-0.25			-74.59%		0.03
NUWENuwellis, Inc.	2.14M	2.37	-0.30	-1.4%	-202.83%	-423.93%		0.08
NSPRInspireMD, Inc.	67.79M	1.60	-2.11	12.96%	-5.94%	-72.06%		0.06
OMOutset Medical, Inc.	95.49M	5.26	-2.14	-12.8%	-73.12%	-61.67%		7.53
SRDXSurmodics, Inc.	614.51M	42.98	-52.41	-4.91%	-14.59%	-15.84%		0.28
AORTArtivion, Inc.	2.05B	43.29	-135.28	9.75%	-2.16%	-2.08%	0.54%	1.31

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	145.9M	180.38M	189.7M	262.84M	276.22M	253.23M	298.84M	313.79M	354M	388.54M
Revenue Growth %	0.01%	0.24%	0.05%	0.39%	0.05%	-0.08%	0.18%	0.05%	0.13%	0.1%
Cost of Goods Sold+	55.18M	61.48M	61.06M	89.86M	93.21M	85.44M	101.32M	111.27M	124.83M	139.76M
COGS % of Revenue	0.38%	0.34%	0.32%	0.34%	0.34%	0.34%	0.34%	0.35%	0.35%	0.36%
Gross Profit+	90.72M	118.9M	128.64M	172.98M	183.01M	167.78M	197.51M	202.52M	229.18M	248.78M
Gross Margin %	0.62%	0.66%	0.68%	0.66%	0.66%	0.66%	0.66%	0.65%	0.65%	0.64%
Gross Profit Growth %	-0.01%	0.31%	0.08%	0.34%	0.06%	-0.08%	0.18%	0.03%	0.13%	0.09%
Operating Expenses+	85.36M	104.99M	120.67M	163.67M	165.97M	165.34M	189.4M	196.32M	223.43M	209.91M
OpEx % of Revenue	0.59%	0.58%	0.64%	0.62%	0.6%	0.65%	0.63%	0.63%	0.63%	0.54%
Selling, General & Admin	74.93M	91.55M	101.21M	140.57M	143.01M	141.14M	169.77M	157.44M	208.98M	192.38M
SG&A % of Revenue	0.51%	0.51%	0.53%	0.53%	0.52%	0.56%	0.57%	0.5%	0.59%	0.5%
Research & Development	10.44M	13.45M	19.46M	23.1M	22.96M	24.21M	35.55M	38.88M	28.71M	28.45M
R&D % of Revenue	0.07%	0.07%	0.1%	0.09%	0.08%	0.1%	0.12%	0.12%	0.08%	0.07%
Other Operating Expenses	-484K	-437K	260K	-141K	0	0	-15.92M	0	-14.25M	-10.92M
Operating Income+	5.35M	21.82M	7.97M	9.31M	17.04M	2.44M	8.12M	6.2M	5.74M	38.87M
Operating Margin %	0.04%	0.12%	0.04%	0.04%	0.06%	0.01%	0.03%	0.02%	0.02%	0.1%
Operating Income Growth %	-0.39%	3.08%	-0.63%	0.17%	0.83%	-0.86%	2.33%	-0.24%	-0.07%	5.77%
EBITDA+	11.22M	30.2M	17.7M	27.41M	35.36M	23.15M	32.09M	28.64M	28.82M	63.08M
EBITDA Margin %	0.08%	0.17%	0.09%	0.1%	0.13%	0.09%	0.11%	0.09%	0.08%	0.16%
EBITDA Growth %	-0.25%	1.69%	-0.41%	0.55%	0.29%	-0.35%	0.39%	-0.11%	0.01%	1.19%
D&A (Non-Cash Add-back)	5.86M	8.38M	9.73M	18.09M	18.32M	20.71M	23.98M	22.44M	23.08M	24.2M
EBIT	5.35M	16.91M	8.44M	12.11M	16.53M	-476K	2.06M	3.24M	3.71M	26.76M
Net Interest Income+	107K	-2.97M	-4.67M	-15.56M	-14.15M	-16.48M	-16.81M	-18.08M	-24.22M	-32.81M
Interest Income	107K	72K	212K	226K	738K	217K	79K	147K	1.08M	1.47M
Interest Expense	0	3.04M	4.88M	15.79M	14.89M	16.7M	16.89M	18.22M	25.3M	34.28M
Other Income/Expense	514K	-3.41M	-4.41M	-15.7M	-15.4M	-19.61M	-22.94M	-21.18M	-27.33M	-46.39M
Pretax Income+	5.87M	18.41M	3.56M	-6.39M	1.64M	-17.17M	-14.83M	-14.98M	-21.59M	-7.51M
Pretax Margin %	0.04%	0.1%	0.02%	-0.02%	0.01%	-0.07%	-0.05%	-0.05%	-0.06%	-0.02%
Income Tax+	1.86M	7.63M	-143K	-2.59M	-76K	-492K	7K	4.21M	9.1M	5.84M
Effective Tax Rate %	0.68%	0.59%	1.04%	0.6%	1.05%	0.97%	1%	1.28%	1.42%	1.78%
Net Income+	4M	10.78M	3.7M	-3.81M	1.72M	-16.68M	-14.83M	-19.19M	-30.69M	-13.36M
Net Margin %	0.03%	0.06%	0.02%	-0.01%	0.01%	-0.07%	-0.05%	-0.06%	-0.09%	-0.03%
Net Income Growth %	-0.45%	1.69%	-0.66%	-2.03%	1.45%	-10.7%	0.11%	-0.29%	-0.6%	0.56%
Net Income (Continuing)	4M	10.78M	3.7M	-2.84M	1.72M	-16.68M	-14.83M	-19.19M	-30.69M	-13.36M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	0.14	0.32	0.11	-0.10	0.05	-0.44	-0.38	-0.48	-0.75	-0.32
EPS Growth %	-0.44%	1.29%	-0.66%	-1.91%	1.45%	-10.76%	0.14%	-0.26%	-0.56%	0.57%
EPS (Basic)	0.14	0.33	0.11	-0.11	0.05	-0.44	-0.38	-0.48	-0.75	-0.32
Diluted Shares Outstanding	28.54M	32.82M	34.16M	36.41M	37.86M	37.86M	38.98M	40.03M	40.74M	41.68M
Basic Shares Outstanding	27.74M	31.86M	33.01M	35.16M	37.12M	37.86M	38.98M	40.03M	40.74M	41.68M
Dividend Payout Ratio	0.85%	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	109.66M	147.23M	179.28M	179.17M	187.39M	234.59M	247.7M	247.33M	280.67M	290.08M
Cash & Short-Term Investments	43.42M	57.34M	40.75M	41.49M	33.77M	61.41M	55.01M	39.35M	58.94M	53.46M
Cash Only	43.42M	57.34M	40.75M	41.49M	33.77M	61.41M	55.01M	39.35M	58.94M	53.46M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	26.67M	30.1M	51.44M	51.43M	55.86M	48.75M	58.1M	69.58M	74.14M	85.89M
Days Sales Outstanding	66.73	60.9	98.98	71.42	73.81	70.27	70.97	80.94	76.44	80.69
Inventory	14.64M	26.29M	46.68M	45.48M	53.07M	73.04M	76.97M	74.48M	81.98M	79.77M
Days Inventory Outstanding	96.86	156.1	279.06	184.73	207.82	312.01	277.28	244.32	239.7	208.32
Other Current Assets	25.57M	31.39M	36.45M	33.92M	33.08M	37.09M	42.86M	46.37M	49.8M	70.96M
Total Non-Current Assets+	71.52M	168.91M	412.39M	391.92M	418.26M	554.82M	545.36M	515.46M	511.73M	499.02M
Property, Plant & Equipment	11.48M	18.5M	33.58M	31.03M	54.14M	51.65M	83.23M	80.53M	82.18M	76.13M
Fixed Asset Turnover	12.70x	9.75x	5.65x	8.47x	5.10x	4.90x	3.59x	3.90x	4.31x	5.10x
Goodwill	11.37M	78.29M	188.31M	188.78M	186.7M	260.06M	250M	243.63M	247.34M	240.96M
Intangible Assets	19.9M	66.64M	179.43M	160.08M	157.73M	227.06M	201.5M	182.65M	172.23M	156.38M
Long-Term Investments	5M	0	1.98M	0	0	0	0	0	0	0
Other Non-Current Assets	5.58M	5.47M	7.49M	7.92M	14.21M	14.6M	8.27M	7.34M	8.89M	24.48M
Total Assets+	181.18M	316.14M	591.67M	571.09M	605.65M	789.4M	793.05M	762.8M	792.4M	789.1M
Asset Turnover	0.81x	0.57x	0.32x	0.46x	0.46x	0.32x	0.38x	0.41x	0.45x	0.49x
Asset Growth %	0.03%	0.74%	0.87%	-0.03%	0.06%	0.3%	0%	-0.04%	0.04%	-0%
Total Current Liabilities+	19.61M	30.1M	42.94M	34.52M	45.2M	60.47M	44.95M	49.67M	57.86M	66.82M
Accounts Payable	4.59M	5.74M	9.77M	7.55M	9.8M	9.62M	10.39M	12M	13.32M	17.97M
Days Payables Outstanding	30.36	34.1	58.38	30.66	38.36	41.11	37.45	39.38	38.94	46.93
Short-Term Debt	0	4.56M	1.3M	1.89M	1.16M	1.2M	1.63M	1.61M	1.45M	195K
Deferred Revenue (Current)	0	1000K	1000K	1000K	0	0	0	0	0	0
Other Current Liabilities	1.33M	10.98M	12.06M	13.86M	14.07M	29.37M	700K	1.31M	21.11M	583K
Current Ratio	5.59x	4.89x	4.18x	5.19x	4.15x	3.88x	5.51x	4.98x	4.85x	4.34x
Quick Ratio	4.85x	4.02x	3.09x	3.87x	2.97x	2.67x	3.80x	3.48x	3.43x	3.15x
Cash Conversion Cycle	133.23	182.89	319.66	225.5	243.28	341.17	310.8	285.88	277.2	242.08
Total Non-Current Liabilities+	6.32M	77.06M	269.69M	261.5M	274.76M	400.22M	447.37M	428.79M	452.75M	446.08M
Long-Term Debt	0	67.01M	218.24M	215.72M	214.57M	290.47M	307.49M	306.5M	305.53M	314.15M
Capital Lease Obligations	0	11K	6.86M	5.94M	23.33M	19.33M	49.24M	44.9M	47.38M	42.82M
Deferred Tax Liabilities	0	7K	30.43M	27.27M	25.84M	34.71M	28.8M	24.5M	21.85M	20.18M
Other Non-Current Liabilities	6.32M	10.03M	14.17M	12.58M	11.02M	55.71M	61.84M	52.9M	77.99M	68.92M
Total Liabilities	25.93M	107.16M	312.63M	296.02M	319.96M	460.69M	492.32M	478.47M	510.62M	512.9M
Total Debt+	0	71.57M	226.39M	223.55M	245.15M	317.37M	362.04M	356.83M	358.34M	362.26M
Net Debt	-43.42M	14.23M	185.63M	182.06M	211.39M	255.96M	307.03M	317.48M	299.4M	308.8M
Debt / Equity	-	0.34x	0.81x	0.81x	0.86x	0.97x	1.20x	1.25x	1.27x	1.31x
Debt / EBITDA	-	2.37x	12.79x	8.16x	6.93x	13.71x	11.28x	12.46x	12.43x	5.74x
Net Debt / EBITDA	-3.87x	0.47x	10.49x	6.64x	5.98x	11.06x	9.57x	11.08x	10.39x	4.90x
Interest Coverage	-	7.17x	1.63x	0.59x	1.14x	0.15x	0.48x	0.34x	0.23x	1.13x
Total Equity+	155.25M	208.98M	279.04M	275.07M	285.7M	328.71M	300.73M	284.33M	281.78M	276.2M
Equity Growth %	0.04%	0.35%	0.34%	-0.01%	0.04%	0.15%	-0.09%	-0.05%	-0.01%	-0.02%
Book Value per Share	5.44	6.37	8.17	7.55	7.55	8.68	7.71	7.10	6.92	6.63
Total Shareholders' Equity	155.25M	208.98M	279.04M	275.07M	285.7M	328.71M	300.73M	284.33M	281.78M	276.2M
Common Stock	298K	342K	376K	385K	390K	404K	414K	418K	426K	434K
Retained Earnings	23.36M	34.14M	37.61M	34.98M	36.7M	20.02M	1.98M	-17.22M	-47.91M	-61.27M
Treasury Stock	-11.22M	-12.13M	-12.72M	-14.59M	-14.59M	-14.65M	-14.65M	-14.65M	-14.65M	-14.65M
Accumulated OCI	-76K	-429K	1.86M	-6.07M	-8.59M	6.74M	-9.89M	-21.61M	-12.01M	-24.93M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	11.44M	19.72M	10.8M	9.88M	15.83M	12.37M	-2.58M	-5.15M	18.82M	22.24M
Operating CF Margin %	0.08%	0.11%	0.06%	0.04%	0.06%	0.05%	-0.01%	-0.02%	0.05%	0.06%
Operating CF Growth %	0.41%	0.72%	-0.45%	-0.09%	0.6%	-0.22%	-1.21%	-0.99%	4.65%	0.18%
Net Income	4M	10.78M	3.7M	-2.84M	1.72M	-3.46M	-14.83M	-19.19M	-30.69M	-13.36M
Depreciation & Amortization	5.86M	8.38M	9.74M	18.09M	18.32M	27.86M	23.98M	22.44M	23.08M	24.2M
Stock-Based Compensation	5.09M	6.33M	6.92M	6.33M	8.8M	6.91M	10.71M	12.34M	14.42M	14.24M
Deferred Taxes	3.68M	595K	-1.48M	-4.49M	-2.31M	4.28M	-4.47M	-1.72M	-1.39M	-1.51M
Other Non-Cash Items	718K	-6.28M	2.79M	2.8M	8.68M	3.47M	15.26M	6.91M	29.59M	15.9M
Working Capital Changes	-7.91M	-83K	-10.87M	-10.01M	-19.38M	-26.7M	-33.23M	-25.94M	-16.19M	-17.24M
Change in Receivables	-3.81M	4.14M	-7.26M	-5.91M	-3.38M	9.94M	-11.56M	-13.34M	-4.05M	-15.39M
Change in Inventory	-2.26M	-9.46M	-9.37M	2.38M	-8.13M	-24.76M	-18.38M	-8.4M	-14.36M	-6.14M
Change in Payables	-656K	4.72M	8.73M	-8.87M	251K	-9.16M	-1.89M	-1.96M	1.68M	9.5M
Cash from Investing+	-4.49M	-73.85M	-170.99M	-6.71M	-23.94M	-73.13M	5.66M	-10.71M	-502K	-28.19M
Capital Expenditures	-4.1M	-7.42M	-7.04M	-5.79M	-8.07M	-7.33M	-13.09M	-10.71M	-7.43M	-11.19M
CapEx % of Revenue	0.03%	0.04%	0.04%	0.02%	0.03%	0.03%	0.04%	0.03%	0.02%	0.03%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	3K	4.87M	-86K	-929K	-15.87M	-6.68M	-249K	0	6.93M	-17M
Cash from Financing+	-2.81M	73.43M	143.25M	-2.56M	-1.49M	93.61M	-12.22M	-1.64M	865K	2.2M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-3.41M	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	1.98M	531K	-7.93M	2.33M	4.03M	949K	-7.22M	2.91M	4.2M	-3.17M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	7.34M	12.29M	3.76M	4.09M	7.75M	5.04M	-15.68M	-15.87M	11.39M	11.05M
FCF Margin %	0.05%	0.07%	0.02%	0.02%	0.03%	0.02%	-0.05%	-0.05%	0.03%	0.03%
FCF Growth %	1.62%	0.68%	-0.69%	0.09%	0.89%	-0.35%	-4.11%	-0.01%	1.72%	-0.03%
FCF per Share	0.26	0.37	0.11	0.11	0.20	0.13	-0.40	-0.40	0.28	0.27
FCF Conversion (FCF/Net Income)	2.86x	1.83x	2.92x	-2.60x	9.20x	-0.74x	0.17x	0.27x	-0.61x	-1.66x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	2.64%	5.92%	1.52%	-1.37%	0.61%	-5.43%	-4.71%	-6.56%	-10.84%	-4.79%
Return on Invested Capital (ROIC)	3.54%	9.77%	1.74%	1.52%	2.68%	0.34%	1.02%	0.77%	0.73%	5%
Gross Margin	62.18%	65.92%	67.81%	65.81%	66.26%	66.26%	66.09%	64.54%	64.74%	64.03%
Net Margin	2.75%	5.98%	1.95%	-1.45%	0.62%	-6.59%	-4.96%	-6.12%	-8.67%	-3.44%
Debt / Equity	-	0.34x	0.81x	0.81x	0.86x	0.97x	1.20x	1.25x	1.27x	1.31x
Interest Coverage	-	7.17x	1.63x	0.59x	1.14x	0.15x	0.48x	0.34x	0.23x	1.13x
FCF Conversion	2.86x	1.83x	2.92x	-2.60x	9.20x	-0.74x	0.17x	0.27x	-0.61x	-1.66x
Revenue Growth	0.87%	23.63%	5.17%	38.55%	5.09%	-8.32%	18.01%	5%	12.82%	9.75%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Aortic Stent Grafts	-	-	-	-	-	-	85.39M	92.75M	107.47M	123.08M
Aortic Stent Grafts Growth	-	-	-	-	-	-	-	8.63%	15.87%	14.53%
Preservation Services	-	-	-	75.45M	78.98M	73.93M	77.24M	83.44M	92.82M	98.31M
Preservation Services Growth	-	-	-	-	4.68%	-6.39%	4.48%	8.02%	11.25%	5.91%
On X	-	34.23M	37.04M	44.83M	50.1M	48.05M	57.36M	63.9M	74.53M	83.98M
On X Growth	-	-	8.21%	21.03%	11.74%	-4.08%	19.37%	11.40%	16.62%	12.69%
Surgical Sealants	-	-	-	-	-	-	70.71M	65.38M	68.02M	73.9M
Surgical Sealants Growth	-	-	-	-	-	-	-	-7.54%	4.03%	8.65%
Other Products	-	-	-	-	-	-	8.13M	8.32M	11.17M	9.27M
Other Products Growth	-	-	-	-	-	-	-	2.27%	34.31%	-17.03%
Products	-	-	-	-	-	179.3M	-	-	-	-
Products Growth	-	-	-	-	-	-	-	-	-	-
Bioglue	-	-	-	-	68.61M	62.07M	-	-	-	-
Bioglue Growth	-	-	-	-	-	-9.54%	-	-	-	-
Aortic Stents And Stent Grafts	-	-	-	-	-	61.66M	-	-	-	-
Aortic Stents And Stent Grafts Growth	-	-	-	-	-	-	-	-	-	-
Cardiac Tissue	28.06M	29.7M	32.51M	35.68M	40.88M	37.89M	-	-	-	-
Cardiac Tissue Growth	-	5.84%	9.47%	9.76%	14.56%	-7.30%	-	-	-	-
Vascular Tissue	34.76M	36.69M	37.56M	39.76M	38.1M	35.85M	-	-	-	-
Vascular Tissue Growth	-	5.56%	2.37%	5.87%	-4.19%	-5.89%	-	-	-	-
Photofix	1.4M	1.87M	2.12M	2.58M	3.75M	4.17M	-	-	-	-
Photofix Growth	-	34.03%	13.09%	21.79%	45.67%	11.05%	-	-	-	-
Per Clot	4.08M	4.02M	3.53M	3.77M	3.79M	2.88M	-	-	-	-
Per Clot Growth	-	-1.52%	-12.14%	6.62%	0.74%	-24.06%	-	-	-	-
Cardiogenesis Cardiac Laser Therapy	9.42M	7.86M	6.87M	6.22M	6.02M	464K	-	-	-	-
Cardiogenesis Cardiac Laser Therapy Growth	-	-16.51%	-12.69%	-9.45%	-3.23%	-92.29%	-	-	-	-
Neopatch	-	-	-	-	-	183K	-	-	-	-
Neopatch Growth	-	-	-	-	-	-	-	-	-	-
Jotec Ag	-	-	4.14M	63.34M	64.97M	-	-	-	-	-
Jotec Ag Growth	-	-	-	1431.46%	2.58%	-	-	-	-	-
Bio Glue And Bio Foam	59.33M	63.46M	65.94M	66.66M	-	-	-	-	-	-
Bio Glue And Bio Foam Growth	-	6.96%	3.90%	1.09%	-	-	-	-	-	-
He R O Graft	7.55M	2.33M	-	-	-	-	-	-	-	-
He R O Graft Growth	-	-69.19%	-	-	-	-	-	-	-	-
Procol	1.3M	218K	-	-	-	-	-	-	-	-
Procol Growth	-	-83.30%	-	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
North America	-	-	-	-	-	-	-	-	-	197.94M
North America Growth	-	-	-	-	-	-	-	-	-	-
Europe, the Middle East, and Africas	-	-	-	-	-	-	-	-	-	131.52M
Europe, the Middle East, and Africas Growth	-	-	-	-	-	-	-	-	-	-
Asia Pacific	-	-	-	-	-	-	-	-	-	37.2M
Asia Pacific Growth	-	-	-	-	-	-	-	-	-	-
Latin America	-	-	-	-	-	-	-	-	-	21.88M
Latin America Growth	-	-	-	-	-	-	-	-	-	-
UNITED STATES	-	-	-	-	-	-	-	161.11M	179.49M	-
UNITED STATES Growth	-	-	-	-	-	-	-	-	11.40%	-
Non-US	-	-	-	-	-	-	-	152.68M	174.52M	-
Non-US Growth	-	-	-	-	-	-	-	-	14.31%	-
U	-	131.73M	135.1M	144.65M	150.55M	138.27M	151.15M	-	-	-
U Growth	-	-	2.56%	7.07%	4.08%	-8.16%	9.31%	-	-	-
Non Us	30.92M	48.65M	54.6M	118.19M	125.67M	114.95M	147.69M	-	-	-
Non Us Growth	-	57.35%	12.22%	116.47%	6.33%	-8.53%	28.47%	-	-	-

Frequently Asked Questions

Growth & Financials

Artivion, Inc. (AORT) reported $422.6M in revenue for fiscal year 2024. This represents a 253% increase from $119.6M in 2011.

Artivion, Inc. (AORT) grew revenue by 9.8% over the past year. This is steady growth.

Artivion, Inc. (AORT) reported a net loss of $9.1M for fiscal year 2024.

Dividend & Returns

Artivion, Inc. (AORT) has a return on equity (ROE) of -4.8%. Negative ROE indicates the company is unprofitable.

Artivion, Inc. (AORT) generated $15.8M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...

Artivion, Inc. (AORT) 10-Year Financial Performance & Capital Metrics

AORT • • Industrial / General

HealthcareMedical DevicesCardiovascular DevicesVascular & Aortic Devices

Revenue $389M +9.8%
EBITDA $63M +118.9%
Net Income -$13M +56.5%
EPS (Diluted) -0.32 +57.3%
Gross Margin 64.03% -1.1%
EBITDA Margin 16.23% +99.4%
Operating Margin 10.01% +516.8%
Net Margin -3.44% +60.3%
ROE -4.79% +55.8%
ROIC 5% +586.7%
Debt/Equity 1.31 +3.1%
Interest Coverage 1.13 +399.7%

Technical Analysis

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y10.39%

5Y7.06%

3Y9.14%

TTM9.81%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-974.15%

EPS CAGR

10Y-

5Y-

3Y-

TTM-991.44%

ROCE

10Y Avg2.83%

5Y Avg1.69%

3Y Avg2.33%

Latest5.34%

Peer Comparison

Vascular & Aortic Devices

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
PENPenumbra, Inc.	13.73B	350.49	973.58	12.86%	12.3%	12.07%	1.07%	0.19
NVNOenVVeno Medical Corporation	6.35M	0.31	-0.25			-74.59%		0.03
NUWENuwellis, Inc.	2.14M	2.37	-0.30	-1.4%	-202.83%	-423.93%		0.08
NSPRInspireMD, Inc.	67.79M	1.60	-2.11	12.96%	-5.94%	-72.06%		0.06
OMOutset Medical, Inc.	95.49M	5.26	-2.14	-12.8%	-73.12%	-61.67%		7.53
SRDXSurmodics, Inc.	614.51M	42.98	-52.41	-4.91%	-14.59%	-15.84%		0.28
AORTArtivion, Inc.	2.05B	43.29	-135.28	9.75%	-2.16%	-2.08%	0.54%	1.31

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	145.9M	180.38M	189.7M	262.84M	276.22M	253.23M	298.84M	313.79M	354M	388.54M
Revenue Growth %	0.01%	0.24%	0.05%	0.39%	0.05%	-0.08%	0.18%	0.05%	0.13%	0.1%
Cost of Goods Sold+	55.18M	61.48M	61.06M	89.86M	93.21M	85.44M	101.32M	111.27M	124.83M	139.76M
COGS % of Revenue	0.38%	0.34%	0.32%	0.34%	0.34%	0.34%	0.34%	0.35%	0.35%	0.36%
Gross Profit+	90.72M	118.9M	128.64M	172.98M	183.01M	167.78M	197.51M	202.52M	229.18M	248.78M
Gross Margin %	0.62%	0.66%	0.68%	0.66%	0.66%	0.66%	0.66%	0.65%	0.65%	0.64%
Gross Profit Growth %	-0.01%	0.31%	0.08%	0.34%	0.06%	-0.08%	0.18%	0.03%	0.13%	0.09%
Operating Expenses+	85.36M	104.99M	120.67M	163.67M	165.97M	165.34M	189.4M	196.32M	223.43M	209.91M
OpEx % of Revenue	0.59%	0.58%	0.64%	0.62%	0.6%	0.65%	0.63%	0.63%	0.63%	0.54%
Selling, General & Admin	74.93M	91.55M	101.21M	140.57M	143.01M	141.14M	169.77M	157.44M	208.98M	192.38M
SG&A % of Revenue	0.51%	0.51%	0.53%	0.53%	0.52%	0.56%	0.57%	0.5%	0.59%	0.5%
Research & Development	10.44M	13.45M	19.46M	23.1M	22.96M	24.21M	35.55M	38.88M	28.71M	28.45M
R&D % of Revenue	0.07%	0.07%	0.1%	0.09%	0.08%	0.1%	0.12%	0.12%	0.08%	0.07%
Other Operating Expenses	-484K	-437K	260K	-141K	0	0	-15.92M	0	-14.25M	-10.92M
Operating Income+	5.35M	21.82M	7.97M	9.31M	17.04M	2.44M	8.12M	6.2M	5.74M	38.87M
Operating Margin %	0.04%	0.12%	0.04%	0.04%	0.06%	0.01%	0.03%	0.02%	0.02%	0.1%
Operating Income Growth %	-0.39%	3.08%	-0.63%	0.17%	0.83%	-0.86%	2.33%	-0.24%	-0.07%	5.77%
EBITDA+	11.22M	30.2M	17.7M	27.41M	35.36M	23.15M	32.09M	28.64M	28.82M	63.08M
EBITDA Margin %	0.08%	0.17%	0.09%	0.1%	0.13%	0.09%	0.11%	0.09%	0.08%	0.16%
EBITDA Growth %	-0.25%	1.69%	-0.41%	0.55%	0.29%	-0.35%	0.39%	-0.11%	0.01%	1.19%
D&A (Non-Cash Add-back)	5.86M	8.38M	9.73M	18.09M	18.32M	20.71M	23.98M	22.44M	23.08M	24.2M
EBIT	5.35M	16.91M	8.44M	12.11M	16.53M	-476K	2.06M	3.24M	3.71M	26.76M
Net Interest Income+	107K	-2.97M	-4.67M	-15.56M	-14.15M	-16.48M	-16.81M	-18.08M	-24.22M	-32.81M
Interest Income	107K	72K	212K	226K	738K	217K	79K	147K	1.08M	1.47M
Interest Expense	0	3.04M	4.88M	15.79M	14.89M	16.7M	16.89M	18.22M	25.3M	34.28M
Other Income/Expense	514K	-3.41M	-4.41M	-15.7M	-15.4M	-19.61M	-22.94M	-21.18M	-27.33M	-46.39M
Pretax Income+	5.87M	18.41M	3.56M	-6.39M	1.64M	-17.17M	-14.83M	-14.98M	-21.59M	-7.51M
Pretax Margin %	0.04%	0.1%	0.02%	-0.02%	0.01%	-0.07%	-0.05%	-0.05%	-0.06%	-0.02%
Income Tax+	1.86M	7.63M	-143K	-2.59M	-76K	-492K	7K	4.21M	9.1M	5.84M
Effective Tax Rate %	0.68%	0.59%	1.04%	0.6%	1.05%	0.97%	1%	1.28%	1.42%	1.78%
Net Income+	4M	10.78M	3.7M	-3.81M	1.72M	-16.68M	-14.83M	-19.19M	-30.69M	-13.36M
Net Margin %	0.03%	0.06%	0.02%	-0.01%	0.01%	-0.07%	-0.05%	-0.06%	-0.09%	-0.03%
Net Income Growth %	-0.45%	1.69%	-0.66%	-2.03%	1.45%	-10.7%	0.11%	-0.29%	-0.6%	0.56%
Net Income (Continuing)	4M	10.78M	3.7M	-2.84M	1.72M	-16.68M	-14.83M	-19.19M	-30.69M	-13.36M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	0.14	0.32	0.11	-0.10	0.05	-0.44	-0.38	-0.48	-0.75	-0.32
EPS Growth %	-0.44%	1.29%	-0.66%	-1.91%	1.45%	-10.76%	0.14%	-0.26%	-0.56%	0.57%
EPS (Basic)	0.14	0.33	0.11	-0.11	0.05	-0.44	-0.38	-0.48	-0.75	-0.32
Diluted Shares Outstanding	28.54M	32.82M	34.16M	36.41M	37.86M	37.86M	38.98M	40.03M	40.74M	41.68M
Basic Shares Outstanding	27.74M	31.86M	33.01M	35.16M	37.12M	37.86M	38.98M	40.03M	40.74M	41.68M
Dividend Payout Ratio	0.85%	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	109.66M	147.23M	179.28M	179.17M	187.39M	234.59M	247.7M	247.33M	280.67M	290.08M
Cash & Short-Term Investments	43.42M	57.34M	40.75M	41.49M	33.77M	61.41M	55.01M	39.35M	58.94M	53.46M
Cash Only	43.42M	57.34M	40.75M	41.49M	33.77M	61.41M	55.01M	39.35M	58.94M	53.46M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	26.67M	30.1M	51.44M	51.43M	55.86M	48.75M	58.1M	69.58M	74.14M	85.89M
Days Sales Outstanding	66.73	60.9	98.98	71.42	73.81	70.27	70.97	80.94	76.44	80.69
Inventory	14.64M	26.29M	46.68M	45.48M	53.07M	73.04M	76.97M	74.48M	81.98M	79.77M
Days Inventory Outstanding	96.86	156.1	279.06	184.73	207.82	312.01	277.28	244.32	239.7	208.32
Other Current Assets	25.57M	31.39M	36.45M	33.92M	33.08M	37.09M	42.86M	46.37M	49.8M	70.96M
Total Non-Current Assets+	71.52M	168.91M	412.39M	391.92M	418.26M	554.82M	545.36M	515.46M	511.73M	499.02M
Property, Plant & Equipment	11.48M	18.5M	33.58M	31.03M	54.14M	51.65M	83.23M	80.53M	82.18M	76.13M
Fixed Asset Turnover	12.70x	9.75x	5.65x	8.47x	5.10x	4.90x	3.59x	3.90x	4.31x	5.10x
Goodwill	11.37M	78.29M	188.31M	188.78M	186.7M	260.06M	250M	243.63M	247.34M	240.96M
Intangible Assets	19.9M	66.64M	179.43M	160.08M	157.73M	227.06M	201.5M	182.65M	172.23M	156.38M
Long-Term Investments	5M	0	1.98M	0	0	0	0	0	0	0
Other Non-Current Assets	5.58M	5.47M	7.49M	7.92M	14.21M	14.6M	8.27M	7.34M	8.89M	24.48M
Total Assets+	181.18M	316.14M	591.67M	571.09M	605.65M	789.4M	793.05M	762.8M	792.4M	789.1M
Asset Turnover	0.81x	0.57x	0.32x	0.46x	0.46x	0.32x	0.38x	0.41x	0.45x	0.49x
Asset Growth %	0.03%	0.74%	0.87%	-0.03%	0.06%	0.3%	0%	-0.04%	0.04%	-0%
Total Current Liabilities+	19.61M	30.1M	42.94M	34.52M	45.2M	60.47M	44.95M	49.67M	57.86M	66.82M
Accounts Payable	4.59M	5.74M	9.77M	7.55M	9.8M	9.62M	10.39M	12M	13.32M	17.97M
Days Payables Outstanding	30.36	34.1	58.38	30.66	38.36	41.11	37.45	39.38	38.94	46.93
Short-Term Debt	0	4.56M	1.3M	1.89M	1.16M	1.2M	1.63M	1.61M	1.45M	195K
Deferred Revenue (Current)	0	1000K	1000K	1000K	0	0	0	0	0	0
Other Current Liabilities	1.33M	10.98M	12.06M	13.86M	14.07M	29.37M	700K	1.31M	21.11M	583K
Current Ratio	5.59x	4.89x	4.18x	5.19x	4.15x	3.88x	5.51x	4.98x	4.85x	4.34x
Quick Ratio	4.85x	4.02x	3.09x	3.87x	2.97x	2.67x	3.80x	3.48x	3.43x	3.15x
Cash Conversion Cycle	133.23	182.89	319.66	225.5	243.28	341.17	310.8	285.88	277.2	242.08
Total Non-Current Liabilities+	6.32M	77.06M	269.69M	261.5M	274.76M	400.22M	447.37M	428.79M	452.75M	446.08M
Long-Term Debt	0	67.01M	218.24M	215.72M	214.57M	290.47M	307.49M	306.5M	305.53M	314.15M
Capital Lease Obligations	0	11K	6.86M	5.94M	23.33M	19.33M	49.24M	44.9M	47.38M	42.82M
Deferred Tax Liabilities	0	7K	30.43M	27.27M	25.84M	34.71M	28.8M	24.5M	21.85M	20.18M
Other Non-Current Liabilities	6.32M	10.03M	14.17M	12.58M	11.02M	55.71M	61.84M	52.9M	77.99M	68.92M
Total Liabilities	25.93M	107.16M	312.63M	296.02M	319.96M	460.69M	492.32M	478.47M	510.62M	512.9M
Total Debt+	0	71.57M	226.39M	223.55M	245.15M	317.37M	362.04M	356.83M	358.34M	362.26M
Net Debt	-43.42M	14.23M	185.63M	182.06M	211.39M	255.96M	307.03M	317.48M	299.4M	308.8M
Debt / Equity	-	0.34x	0.81x	0.81x	0.86x	0.97x	1.20x	1.25x	1.27x	1.31x
Debt / EBITDA	-	2.37x	12.79x	8.16x	6.93x	13.71x	11.28x	12.46x	12.43x	5.74x
Net Debt / EBITDA	-3.87x	0.47x	10.49x	6.64x	5.98x	11.06x	9.57x	11.08x	10.39x	4.90x
Interest Coverage	-	7.17x	1.63x	0.59x	1.14x	0.15x	0.48x	0.34x	0.23x	1.13x
Total Equity+	155.25M	208.98M	279.04M	275.07M	285.7M	328.71M	300.73M	284.33M	281.78M	276.2M
Equity Growth %	0.04%	0.35%	0.34%	-0.01%	0.04%	0.15%	-0.09%	-0.05%	-0.01%	-0.02%
Book Value per Share	5.44	6.37	8.17	7.55	7.55	8.68	7.71	7.10	6.92	6.63
Total Shareholders' Equity	155.25M	208.98M	279.04M	275.07M	285.7M	328.71M	300.73M	284.33M	281.78M	276.2M
Common Stock	298K	342K	376K	385K	390K	404K	414K	418K	426K	434K
Retained Earnings	23.36M	34.14M	37.61M	34.98M	36.7M	20.02M	1.98M	-17.22M	-47.91M	-61.27M
Treasury Stock	-11.22M	-12.13M	-12.72M	-14.59M	-14.59M	-14.65M	-14.65M	-14.65M	-14.65M	-14.65M
Accumulated OCI	-76K	-429K	1.86M	-6.07M	-8.59M	6.74M	-9.89M	-21.61M	-12.01M	-24.93M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	11.44M	19.72M	10.8M	9.88M	15.83M	12.37M	-2.58M	-5.15M	18.82M	22.24M
Operating CF Margin %	0.08%	0.11%	0.06%	0.04%	0.06%	0.05%	-0.01%	-0.02%	0.05%	0.06%
Operating CF Growth %	0.41%	0.72%	-0.45%	-0.09%	0.6%	-0.22%	-1.21%	-0.99%	4.65%	0.18%
Net Income	4M	10.78M	3.7M	-2.84M	1.72M	-3.46M	-14.83M	-19.19M	-30.69M	-13.36M
Depreciation & Amortization	5.86M	8.38M	9.74M	18.09M	18.32M	27.86M	23.98M	22.44M	23.08M	24.2M
Stock-Based Compensation	5.09M	6.33M	6.92M	6.33M	8.8M	6.91M	10.71M	12.34M	14.42M	14.24M
Deferred Taxes	3.68M	595K	-1.48M	-4.49M	-2.31M	4.28M	-4.47M	-1.72M	-1.39M	-1.51M
Other Non-Cash Items	718K	-6.28M	2.79M	2.8M	8.68M	3.47M	15.26M	6.91M	29.59M	15.9M
Working Capital Changes	-7.91M	-83K	-10.87M	-10.01M	-19.38M	-26.7M	-33.23M	-25.94M	-16.19M	-17.24M
Change in Receivables	-3.81M	4.14M	-7.26M	-5.91M	-3.38M	9.94M	-11.56M	-13.34M	-4.05M	-15.39M
Change in Inventory	-2.26M	-9.46M	-9.37M	2.38M	-8.13M	-24.76M	-18.38M	-8.4M	-14.36M	-6.14M
Change in Payables	-656K	4.72M	8.73M	-8.87M	251K	-9.16M	-1.89M	-1.96M	1.68M	9.5M
Cash from Investing+	-4.49M	-73.85M	-170.99M	-6.71M	-23.94M	-73.13M	5.66M	-10.71M	-502K	-28.19M
Capital Expenditures	-4.1M	-7.42M	-7.04M	-5.79M	-8.07M	-7.33M	-13.09M	-10.71M	-7.43M	-11.19M
CapEx % of Revenue	0.03%	0.04%	0.04%	0.02%	0.03%	0.03%	0.04%	0.03%	0.02%	0.03%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	3K	4.87M	-86K	-929K	-15.87M	-6.68M	-249K	0	6.93M	-17M
Cash from Financing+	-2.81M	73.43M	143.25M	-2.56M	-1.49M	93.61M	-12.22M	-1.64M	865K	2.2M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-3.41M	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	1.98M	531K	-7.93M	2.33M	4.03M	949K	-7.22M	2.91M	4.2M	-3.17M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	7.34M	12.29M	3.76M	4.09M	7.75M	5.04M	-15.68M	-15.87M	11.39M	11.05M
FCF Margin %	0.05%	0.07%	0.02%	0.02%	0.03%	0.02%	-0.05%	-0.05%	0.03%	0.03%
FCF Growth %	1.62%	0.68%	-0.69%	0.09%	0.89%	-0.35%	-4.11%	-0.01%	1.72%	-0.03%
FCF per Share	0.26	0.37	0.11	0.11	0.20	0.13	-0.40	-0.40	0.28	0.27
FCF Conversion (FCF/Net Income)	2.86x	1.83x	2.92x	-2.60x	9.20x	-0.74x	0.17x	0.27x	-0.61x	-1.66x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	2.64%	5.92%	1.52%	-1.37%	0.61%	-5.43%	-4.71%	-6.56%	-10.84%	-4.79%
Return on Invested Capital (ROIC)	3.54%	9.77%	1.74%	1.52%	2.68%	0.34%	1.02%	0.77%	0.73%	5%
Gross Margin	62.18%	65.92%	67.81%	65.81%	66.26%	66.26%	66.09%	64.54%	64.74%	64.03%
Net Margin	2.75%	5.98%	1.95%	-1.45%	0.62%	-6.59%	-4.96%	-6.12%	-8.67%	-3.44%
Debt / Equity	-	0.34x	0.81x	0.81x	0.86x	0.97x	1.20x	1.25x	1.27x	1.31x
Interest Coverage	-	7.17x	1.63x	0.59x	1.14x	0.15x	0.48x	0.34x	0.23x	1.13x
FCF Conversion	2.86x	1.83x	2.92x	-2.60x	9.20x	-0.74x	0.17x	0.27x	-0.61x	-1.66x
Revenue Growth	0.87%	23.63%	5.17%	38.55%	5.09%	-8.32%	18.01%	5%	12.82%	9.75%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Aortic Stent Grafts	-	-	-	-	-	-	85.39M	92.75M	107.47M	123.08M
Aortic Stent Grafts Growth	-	-	-	-	-	-	-	8.63%	15.87%	14.53%
Preservation Services	-	-	-	75.45M	78.98M	73.93M	77.24M	83.44M	92.82M	98.31M
Preservation Services Growth	-	-	-	-	4.68%	-6.39%	4.48%	8.02%	11.25%	5.91%
On X	-	34.23M	37.04M	44.83M	50.1M	48.05M	57.36M	63.9M	74.53M	83.98M
On X Growth	-	-	8.21%	21.03%	11.74%	-4.08%	19.37%	11.40%	16.62%	12.69%
Surgical Sealants	-	-	-	-	-	-	70.71M	65.38M	68.02M	73.9M
Surgical Sealants Growth	-	-	-	-	-	-	-	-7.54%	4.03%	8.65%
Other Products	-	-	-	-	-	-	8.13M	8.32M	11.17M	9.27M
Other Products Growth	-	-	-	-	-	-	-	2.27%	34.31%	-17.03%
Products	-	-	-	-	-	179.3M	-	-	-	-
Products Growth	-	-	-	-	-	-	-	-	-	-
Bioglue	-	-	-	-	68.61M	62.07M	-	-	-	-
Bioglue Growth	-	-	-	-	-	-9.54%	-	-	-	-
Aortic Stents And Stent Grafts	-	-	-	-	-	61.66M	-	-	-	-
Aortic Stents And Stent Grafts Growth	-	-	-	-	-	-	-	-	-	-
Cardiac Tissue	28.06M	29.7M	32.51M	35.68M	40.88M	37.89M	-	-	-	-
Cardiac Tissue Growth	-	5.84%	9.47%	9.76%	14.56%	-7.30%	-	-	-	-
Vascular Tissue	34.76M	36.69M	37.56M	39.76M	38.1M	35.85M	-	-	-	-
Vascular Tissue Growth	-	5.56%	2.37%	5.87%	-4.19%	-5.89%	-	-	-	-
Photofix	1.4M	1.87M	2.12M	2.58M	3.75M	4.17M	-	-	-	-
Photofix Growth	-	34.03%	13.09%	21.79%	45.67%	11.05%	-	-	-	-
Per Clot	4.08M	4.02M	3.53M	3.77M	3.79M	2.88M	-	-	-	-
Per Clot Growth	-	-1.52%	-12.14%	6.62%	0.74%	-24.06%	-	-	-	-
Cardiogenesis Cardiac Laser Therapy	9.42M	7.86M	6.87M	6.22M	6.02M	464K	-	-	-	-
Cardiogenesis Cardiac Laser Therapy Growth	-	-16.51%	-12.69%	-9.45%	-3.23%	-92.29%	-	-	-	-
Neopatch	-	-	-	-	-	183K	-	-	-	-
Neopatch Growth	-	-	-	-	-	-	-	-	-	-
Jotec Ag	-	-	4.14M	63.34M	64.97M	-	-	-	-	-
Jotec Ag Growth	-	-	-	1431.46%	2.58%	-	-	-	-	-
Bio Glue And Bio Foam	59.33M	63.46M	65.94M	66.66M	-	-	-	-	-	-
Bio Glue And Bio Foam Growth	-	6.96%	3.90%	1.09%	-	-	-	-	-	-
He R O Graft	7.55M	2.33M	-	-	-	-	-	-	-	-
He R O Graft Growth	-	-69.19%	-	-	-	-	-	-	-	-
Procol	1.3M	218K	-	-	-	-	-	-	-	-
Procol Growth	-	-83.30%	-	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
North America	-	-	-	-	-	-	-	-	-	197.94M
North America Growth	-	-	-	-	-	-	-	-	-	-
Europe, the Middle East, and Africas	-	-	-	-	-	-	-	-	-	131.52M
Europe, the Middle East, and Africas Growth	-	-	-	-	-	-	-	-	-	-
Asia Pacific	-	-	-	-	-	-	-	-	-	37.2M
Asia Pacific Growth	-	-	-	-	-	-	-	-	-	-
Latin America	-	-	-	-	-	-	-	-	-	21.88M
Latin America Growth	-	-	-	-	-	-	-	-	-	-
UNITED STATES	-	-	-	-	-	-	-	161.11M	179.49M	-
UNITED STATES Growth	-	-	-	-	-	-	-	-	11.40%	-
Non-US	-	-	-	-	-	-	-	152.68M	174.52M	-
Non-US Growth	-	-	-	-	-	-	-	-	14.31%	-
U	-	131.73M	135.1M	144.65M	150.55M	138.27M	151.15M	-	-	-
U Growth	-	-	2.56%	7.07%	4.08%	-8.16%	9.31%	-	-	-
Non Us	30.92M	48.65M	54.6M	118.19M	125.67M	114.95M	147.69M	-	-	-
Non Us Growth	-	57.35%	12.22%	116.47%	6.33%	-8.53%	28.47%	-	-	-

Frequently Asked Questions

Growth & Financials

Artivion, Inc. (AORT) reported $422.6M in revenue for fiscal year 2024. This represents a 253% increase from $119.6M in 2011.

Artivion, Inc. (AORT) grew revenue by 9.8% over the past year. This is steady growth.

Artivion, Inc. (AORT) reported a net loss of $9.1M for fiscal year 2024.

Dividend & Returns

Artivion, Inc. (AORT) has a return on equity (ROE) of -4.8%. Negative ROE indicates the company is unprofitable.

Artivion, Inc. (AORT) generated $15.8M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.